POXEL, headquartered France, and with subsidiaries in Japan, is a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). The company has recently announced the appointment of David E. Moller, MD, as Chief Scientific Officer (CSO). Dr. Moller will be responsible for leading scientific-related activities to support the advancement of the Company, including scientific innovation and scientific communications at Poxel. Dr. Moller is an industry leader in the discovery and development of new therapeutic agents, particularly in diabetes and metabolic disorders. He will be based in Boston, further expanding Poxel’s presence in the U.S.

Dr. Moller will join the executive management team and work closely with the R&D team in France, including Sébastien Bolze, PharmD, PhD, who has been appointed to the newly created position of Chief Operating Officer, Executive Vice President, Non-Clinical & Manufacturing Operations. In this new role, Dr. Bolze will oversee and coordinate R&D operations.

“With an unmatched depth of expertise in metabolic disease research and drug development, David is a valuable addition to Poxel’s senior management team. This is a critical and exciting time for the Company as we support our partners Sumitomo Dainippon Pharma with product registration for Imeglimin in Japan, and Metavant, a subsidiary of Roivant Sciences, with their preparation for a Phase 3 program for Imeglimin in the U.S. and Europe, while advancing our two NASH programs, PXL770 and PXL065, through key clinical studies,” commented Thomas Kuhn, CEO of Poxel. “David is a highly respected medical expert and scientific leader and we look forward to his contributions as Poxel continues to establish itself at the forefront of innovation in treating metabolic diseases.”

“I am thrilled to join Poxel at this stage of the Company’s evolution. With the successful completion of the Phase 3 program for Imeglimin in Japan, Poxel has achieved a significant milestone for this innovative product candidate; this is a major achievement, especially in a large indication like type 2 diabetes,” said Dr. Moller, CSO of Poxel. “I am excited to join the Company to support the next phase of pipeline development, build momentum in the two NASH clinical programs and apply my experience to complement the Poxel team in expanding its early stage drug development efforts.”

Dr. Moller brings over 20 years of experience leading R&D efforts at Eli Lilly and Company and Merck, where he focused on cardiometabolic drug discovery and development as well as other disease areas including endocrine and musculoskeletal disorders. He joins Poxel from Sigilon Therapeutics, where as CSO he led the company’s rare disease and type 1 diabetes efforts. Prior to that, Dr. Moller served in senior roles at Eli Lilly over a twelve-year period, including Vice President (VP) of Endocrine and Cardiovascular Research and Clinical Investigation and VP of Business Development – Emerging Technology and Innovation. Importantly, his team was responsible for the development of Trulicity^®* (dulaglutide) and other key product candidates. Prior to Eli Lilly, Dr. Moller served in senior roles over a ten-year period at Merck. As VP of Metabolic Disorders, he led the global diabetes and obesity discovery area, which included oversight of the team that discovered Januvia^®* (sitagliptin).

Dr. Moller obtained a BS from Brown University and a Doctor of Medicine degree from the University of Cincinnati. He began his career as Assistant Professor at Harvard Medical School focused on elucidating the pathophysiology of type 2 diabetes, where he had also completed a research and clinical postdoctoral fellowship in Endocrinology. He has published more than 130 peer-reviewed papers. His honors include election to the American Society of Clinical Investigation, the Association of American Physicians, and appointment as an Adjunct Professor at the Karolinska Institute.